ST Bering (002424.SZ): 1.26% of shares have been repurchased cumulatively
Glonghui, May 22丨ST Bering (002424.SZ) announced that as of May 22, 2024, the total number of shares repurchased by the company through centralized bidding transactions through the stock repurchase special securities account was 17,724,812 shares, accounting for 1.26% of the company's current total share capital. The highest transaction price was 8.22 yuan/share, the minimum transaction price was 4.03 yuan/share, and the total transaction amount was 110,967,693.20 yuan (excluding transaction fees).
It's Down 26% But Guizhou Bailing Group Pharmaceutical Co., Ltd. (SZSE:002424) Could Be Riskier Than It Looks
The Guizhou Bailing Group Pharmaceutical Co., Ltd. (SZSE:002424) share price has fared very poorly over the last month, falling by a substantial 26%. Instead of being rewarded, shareholders who hav
ST Bering (002424.SZ): Accumulated cost of 84.62 million yuan to buy back 0.83% of shares
Glonghui, May 7 | ST Bering (002424.SZ) announced that as of April 30, 2024, the total number of shares repurchased by the company through centralized bidding transactions through the stock repurchase special securities account was 11,668,812 shares, accounting for 0.83% of the company's current total share capital. The highest transaction price was 8.22 yuan/share, the minimum transaction price was 6.59 yuan/share, and the total transaction amount was 84,620,058.20 yuan (excluding transaction fees).
Guizhou Bailing (002424.SZ) announced first-quarter results, net profit of 51.6951 million yuan, a decrease of 44.00%
According to the Zhitong Finance App, Guizhou Bailing (002424.SZ) released its report for the first quarter of 2024. The company's revenue was 1,333 billion yuan, an increase of 22.09% over the previous year. Net profit attributable to shareholders of listed companies was RMB 51.6951 million, a year-on-year decrease of 44.00%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 44.6057 million yuan, a year-on-year decrease of 49.57%. Basic earnings per share were $0.04.
Guizhou Bailing (002424.SZ) was approved as the first grade 2 protected variety of traditional Chinese medicine
Guizhou Bailing (002424.SZ) announced, recently, the China Drug Administration (“State Drug Administration”)...
Guizhou Bailing (002424.SZ) has repurchased a total of 0.83% of its shares at a cost of about 84.62 million yuan
Guizhou Bailing (002424.SZ) issued an announcement. As of March 31, 2024, the company has approved share repurchases...
Painful Week for Retail Investors Invested in Guizhou Bailing Group Pharmaceutical Co., Ltd. (SZSE:002424) After 5.5% Drop, Institutions Also Suffered Losses
Key Insights Guizhou Bailing Group Pharmaceutical's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 21 investo
Guizhou Bailing (002424.SZ): Accumulated cost of 84.621 million yuan to buy back 0.83% of shares
Gelonghui, March 4, 丨 Guizhou Bailing (002424.SZ) announced that as of February 29, 2024, the total number of shares repurchased by the company through centralized bidding transactions through the stock repurchase special securities account was 11,668,812 shares, accounting for 0.83% of the company's current total share capital. The highest transaction price was 8.22 yuan/share, the minimum transaction price was 6.59 yuan/share, and the total transaction amount was 84.621 million yuan (excluding transaction fees).
Here's Why Guizhou Bailing Group Pharmaceutical (SZSE:002424) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usu
Guizhou Bailing (002424.SZ): “Multi-center clinical research and mechanism discussion on the prevention of diabetes and retinal complications with the Miao Drug Tangning Tongluo Tablets” passed the acceptance
<国家中医药管理局科技司关于2021年度中医药科学技术研究专项部分课题验收结果的通知>Gelonghui, February 19, Guizhou Bailing (002424.SZ) announced that the company (recently received the “Notice on Forwarding” from the Guizhou Provincial Administration of Traditional Chinese Medicine), according to the “Notice of the Science and Technology Department of the State Administration of Traditional Chinese Medicine on the Acceptance Results of the 2021 Traditional Chinese Medicine Science and Technology Research Special Topics” (China Traditional Chinese Medicine Science and Technology Letter [2024] No. 28), after expert review and combined with the completion of the assessment indicators, the company “Miaoyao Duangning” Tongluo tablets to prevent diabetes and vision
Guizhou Bailing (002424.SZ): Initial repurchase of 6.7036 million shares involving 45.6863 million yuan
Glonghui, Feb. 6 | Guizhou Bailing (002424.SZ) announced that on February 5, 2024, the company repurchased 670.3612 million shares of the company's shares through a dedicated securities account through centralized bidding, accounting for 0.48% of the company's total share capital; the highest transaction price for the initial share repurchase was 6.94 yuan/share, the minimum transaction price was 6.59 yuan/share, and the total amount of capital used was 456.8863 million yuan (excluding transaction fees).
Guizhou Bailing Group Pharmaceutical Co., Ltd.'s (SZSE:002424) Earnings Haven't Escaped The Attention Of Investors
When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 27x, you may consider Guizhou Bailing Group Pharmaceutical Co., Ltd. (SZSE:002424) as a stock to avoid entire
Bailing Group Pharma Gets Green Light for Clinical Trial of New Hepatitis B Drug
Guizhou Bailing Group Pharmaceutical (SHE:002424) has received ethical review approval for a clinical trial of Tifentex tablets in combination with Entecavir tablets for the treatment of chronic hepat
Guizhou Bailing (002424.SZ): Clinical study on the interaction between tifentai tablets and entecavir tablets obtained ethical review approval
Guizhou Bailing (002424.SZ) issued an announcement. Recently, the company received Beijing You'an Hospital affiliated to Capital Medical University...
Guizhou Bailing (002424.SZ): As of November 30, 2023, the total number of shareholders in the company is 101193
Gelonghui, December 22|Guizhou Bailing (002424.SZ) stated on the investor interactive platform that as of November 30, 2023, the total number of shareholders in the company was 101,193.
Guizhou Bailing (002424.SZ): Guizhou Securities Regulatory Bureau ordered the company to take corrective measures
Guizhou Bailing (002424.SZ) announced that the company received the Guizhou Securities Regulatory Bureau's “On Pharmaceuticals for Guizhou Bailing Enterprise Group...
Positive Earnings Growth Hasn't Been Enough to Get Guizhou Bailing Group Pharmaceutical (SZSE:002424) Shareholders a Favorable Return Over the Last Year
It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make higher profits, but you also face the risk of under-performance. That downside risk
Guizhou Bailing (002424.SZ): Chlorpheniramine maleate tablets passed a consistent evaluation of the quality and efficacy of generic drugs
Gelonghui on December 5 | Guizhou Bailing (002424.SZ) announced that recently, Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd. received the “Notice of Approval of Supplemental Application for Drug Supplement” for chlorpheniramine maleate tablets approved and issued by the State Drug Administration. After review, the product passed the generic drug quality and efficacy consistency evaluation. Chlorpheniramine maleate tablets are antihistamines used to treat allergic rhinitis, colds, sinusitis, and allergic skin diseases such as urticaria, allergic drug rash or eczema, angioedema, and itchy skin caused by insect bites.
Guizhou Bailing (002424.SZ) plans to invest in a wholly-owned subsidiary in Hengqin New District of Zhuhai to enhance its comprehensive strength
Guizhou Bailing (002424.SZ) announced that according to business development needs, the company plans to be located in Hengqin, Zhuhai, Guangdong Province...
Guizhou Bailing (002424.SZ): Plans to establish Bailing Yuxiu (Zhuhai) Pharmaceutical for 20 million yuan
Gelonghui November 24丨Guizhou Bailing (002424.SZ) announced that according to business development needs, the company plans to invest 20 million yuan in monetary capital to establish a wholly-owned subsidiary “Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd.” (provisional name, subject to industrial and commercial registration). The establishment of a wholly-owned subsidiary is conducive to improving the company's industrial layout, better developing markets, and enhancing the company's drug research and development capabilities.
No Data